Where Will Pfizer Be in 3 Years?

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.
STAT

The $10 billion question: Will Pfizer hit it big with Metsera, or have regrets?

At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera. It's also taking on a lot of risk.
Fierce Biotech

With Summit leading the pack in PD-1xVEGF bispecifics, Pfizer lays out its own plan to replace Keytruda

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its

Why a Strong Quarter Wasn't Enough to Send Shares of Pfizer Soaring

Pfizer not only beat expectations last quarter, but also boosted its guidance.

Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, with more money and help from the Trump administration
Feedback